Form D · Biotechnology
Cyteir Therapeutics, Inc.
Lexington, MA · CIK 0001662244
Offering snapshot reported Feb 17, 2021 · SEC filing
- Reported sold
- $80M Indefinite offering
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 5, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 17, 2021 | Initial | $79,999,980 | No comparison | 22 | SEC filing |
| Oct 15, 2019 | Initial | $20,200,000 | No comparison | 6 | SEC filing |
| May 16, 2018 | Amendment | $5,833,326 | $1,015,497vs Mar 28, 2018 | 12 | SEC filing |
| Mar 28, 2018 | Initial | $4,817,829 | No comparison | 11 | SEC filing |
| Nov 16, 2016 | Amendment | $5,817,996 | $100,000vs Dec 30, 2015 | 15 | SEC filing |
| Dec 30, 2015 | Initial | $5,717,996 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-389697
Source: Form D, filed Feb 17, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| William B. Asher, Jr. | Executive |
| Racquel Bracken | Director |
| Donald Corcoran | Director, Executive |
| Andrew Gengos | Executive |
| Jean George | Director |
| Ronald Goldstein | Executive |
| Karen Hong | Director |
| Barry Mills | Director |
| Kevin Mills | Director, Executive |
| Susan Molineaux | Director |
| Janwillem Naesens | Director |
| Markus Renschler | Director, Executive |
| Timothy Romberger | Director |
| Paul Secrist | Executive |
| Bart Van Hooland | Director |
| Joseph S. Zakrzewski | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
128 Spring Street Building A, Suite 510
Lexington, MA, 02421
Lexington, MA, 02421